Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.
infoJourney Medical is a micro cap stock with a total market cap of 39.20M.
infoThey trade on the NASDAQ and had their IPO 1 year and 9 months ago.
infoJourney Medical currently employs 20 people.
infoAs of Wednesday, Aug 23 2023, Journey Medical’s share price is $2.03.
News Relating to Journey Medical
Seeking Alpha
Journey Medical Corporation (DERM) Q2 2023 Earnings Call Transcript
Saturday Aug 12 2023 at 10:15
Journey Medical Corporation (NASDAQ:DERM ) Q2 2023 Earnings Conference Call August 8, 2023 4:00 PM ET Company Participants Matt Blazei – CoreIR Claude Maraoui – Co-Founder, President and Chief Executive Officer Joseph Benesch – Interim Chief Financial Officer Srinivas Sidgiddi – Vice President of R&D Neal Bhatia – Director of Clinical Dermatology at Therapeutics Clinical Research Conference Call Participants Scott Henry – Roth capital Kalpit Patel – B. Riley Securities Operator Ladies and Gentleman, thank you for standing by.
Zacks Investment Research
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
Tuesday Aug 08 2023 at 19:42
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.43 per share a year ago.
GlobeNewsWire
Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023
Wednesday Jul 19 2023 at 08:30
Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023 Company to host conference call to discuss financial results and provide a corporate update the week of August 7, 2023
Zacks Investment Research
Journey Medical (DERM) to Post Skin Disease Data, Stock Rises 26%
Tuesday Jul 04 2023 at 09:14
Journey Medical (DERM) rises 26% on Monday after announcing the tentative date for reporting top-line results from its late-stage studies evaluating DFD-29 in treating papulopustular rosacea.
Zacks Investment Research
Journey Medical (DERM) Up on Rosacea Candidate’s Positive Data
Wednesday Jun 14 2023 at 13:13
Journey Medical’s (DERM) phase I study, assessing the impact of DFD-29 on the microbial flora of healthy adults, obtains its primary endpoints.
Zacks Investment Research
Journey Medical Corporation (DERM) Reports Q1 Loss, Lags Revenue Estimates
Monday May 22 2023 at 18:21
Journey Medical Corporation (DERM) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.08 per share a year ago.
GlobeNewsWire
Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023
Friday May 19 2023 at 16:01
Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on May 22, 2023 at 4:30 p.m. ET
Seeking Alpha
Journey Medical Corp (DERM) Q4 2022 Earnings Call Transcript
Wednesday Mar 29 2023 at 22:13
Journey Medical Corp (NASDAQ:DERM ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Founder, President, CEO & Director Joseph Benesch – Interim CFO Srinivas Sidgiddi – VP, Clinical Development & Medical Affairs Conference Call Participants Brandon Folkes – Cantor Fitzgerald Scott Henry – ROTH MKM Partners Andrew Fleszar – B. Riley Securities Operator Ladies and gentlemen, thank you for standing by.
Zacks Investment Research
Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates
Wednesday Mar 29 2023 at 18:19
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Journey Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023
Wednesday Mar 22 2023 at 09:00
Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on March 29, 2023 at 4:30 p.m. ET
Seeking Alpha
Journey Medical Corporation (DERM) Q3 2022 Earnings Call Transcript
Saturday Nov 12 2022 at 09:50
Journey Medical Corporation (NASDAQ:DERM ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Matt Blazei – CORE IR Claude Maraoui – Co-Founder, President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Conference Call Participants Scott Henry – ROTH Capital Brandon Folkes – Cantor Fitzgerald Operator Ladies and gentlemen, thank you for standing by. Good afternoon, and welcome to the Journey Medical’s Third Quarter 2022 Financial Results and Corporate Update Conference Call.
Zacks Investment Research
Journey Medical Corporation (DERM) Reports Q3 Loss, Misses Revenue Estimates
Thursday Nov 10 2022 at 18:48
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -67.65% and 11.59%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
Thursday Nov 03 2022 at 08:52
Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a corporate update on November 10, 2022 at 4:30 p.m. ET
GlobeNewsWire
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
Tuesday Oct 04 2022 at 08:30
SCOTTSDALE, Ariz., Oct. 04, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, President and Chief Executive Officer, will participate in two upcoming investor conferences.
Seeking Alpha
Journey Medical Corporation (DERM) CEO Claude Maraoui on Q2 2022 Results – Earnings Call Transcript
Wednesday Aug 10 2022 at 08:06
Journey Medical Corporation (NASDAQ:DERM ) Q2 2022 Results Conference Call August 9, 2022 4:30 PM ET Company Participants Claude Maraoui – Co-Founder President and Chief Executive Officer Ernest De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Dr. Srinivas Sidgiddi – Vice President of Clinical Development and Medical Affairs Jules Abraham – IR, CORE IR Conference Call Participants Brandon Folkes – Cantor Fitzgerald Mayank Mamtani – B. Riley FBR Operator Ladies and gentlemen, thank you for standing by.
Zacks Investment Research
Journey Medical Corporation (DERM) Reports Q2 Loss, Lags Revenue Estimates
Tuesday Aug 09 2022 at 19:33
Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -72% and 13.97%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Journey Medical Corporation (DERM) CEO Claude Maraoui on Q1 2022 Results – Earnings Call Transcript
Sunday May 15 2022 at 11:46
Journey Medical Corporation (NASDAQ:DERM ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jose Ibrahim – IR Claude Maraoui – Co-Founder, President and Chief Executive Officer Ernie De Paolantonio – Chief Financial Officer Ramsey Alloush – General Counsel Conference Call Participants Kalpit Patel – B. Riley Brandon Folkes – Cantor Fitzgerald Scott Henry – ROTH Capital Operator Ladies and gentlemen, thank you for standing by.
Zacks Investment Research
Journey Medical Corporation (DERM) May Find a Bottom Soon, Here’s Why You Should Buy the Stock Now
Friday Apr 15 2022 at 11:17
After losing some value lately, a hammer chart pattern has been formed for Journey Medical Corporation (DERM), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Seeking Alpha
Journey Medical Aims For $35 Million IPO
Thursday Nov 11 2021 at 13:17
Journey Medical Corporation has filed proposed terms for a $35.2 million IPO. The firm develops and sells treatments for skin conditions.
Journey Medical Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Journey Medical’s Altman Z-score is -2.47 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Journey Medical Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 2 insiders have sold $43.72K of common stock in Journey Medical on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Journey Medical’s Income Quality of 0.31 is lower than its Industry Group of 0.69 (-55.1% lower)
Journey Medical’s Income Quality of 0.31 is lower than its Major Industry Group of 0.71 (-56.3% lower)
Journey Medical’s Income Quality of 0.31 is lower than its Sector of 0.75 (-58.7% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Journey Medical’s Current Ratio of 0.7 is lower than its Industry Group of 4.76 (-85.3% lower)
Journey Medical’s Current Ratio of 0.7 is lower than its Major Industry Group of 4.32 (-83.8% lower)
Journey Medical’s Current Ratio of 0.7 is lower than its Sector of 2.6 (-73.1% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.0 & -1.27)
Cannot compare a negative PE Ratio (-1.0 & -1.1)
Cannot compare a negative PE Ratio (-1.0 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Journey Medical’s PB Ratio of 7839.9 is greater than its Industry Group of 1.34 (584967.2% greater)
Journey Medical’s PB Ratio of 7839.9 is greater than its Major Industry Group of 1.4 (559892.9% greater)
Journey Medical’s PB Ratio of 7839.9 is greater than its Sector of 1.62 (483844.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Journey Medical’s ROE of -7829.2 is lower than its Industry Group of -0.44 (-1779263.6% lower)
Journey Medical’s ROE of -7829.2 is lower than its Major Industry Group of -0.38 (-2060215.8% lower)
Journey Medical’s ROE of -7829.2 is lower than its Sector of -0.03 (-26097233.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Journey Medical’s ROCE of -23.62 is lower than its Industry Group of -0.42 (-5523.8% lower)
Journey Medical’s ROCE of -23.62 is lower than its Major Industry Group of -0.37 (-6283.8% lower)
Journey Medical’s ROCE of -23.62 is lower than its Sector of -0.04 (-58950.0% lower)
Derived from SEC.GOV filing dataopen_in_new